These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 26628427

  • 21. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Seufert J.
    Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [How I treat...The choice between a sulphonylulrea and a gliptin to manage hyperglycaemia in type 2 diabetes].
    Scheen AJ.
    Rev Med Liege; 2014 Sep; 69(9):476-84. PubMed ID: 25796755
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Clinical decisions. Glycemic management in a patient with type 2 diabetes.
    Hirsch IB, Molitch ME.
    N Engl J Med; 2013 Oct 03; 369(14):1370-2. PubMed ID: 24088099
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S, Deng J, Shi L, Mu Y, Dong H.
    J Med Econ; 2015 Oct 03; 18(10):808-20. PubMed ID: 25950193
    [Abstract] [Full Text] [Related]

  • 29. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May 03; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Can genetics improve precision of therapy in diabetes?
    Groop L, Storm P, Rosengren A.
    Trends Endocrinol Metab; 2014 Sep 03; 25(9):440-3. PubMed ID: 25028244
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y, Hong T.
    Diabetes Obes Metab; 2014 Feb 03; 16(2):111-7. PubMed ID: 23668534
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Follow-up of intensive glucose control in type 2 diabetes.
    Mühlhauser I.
    N Engl J Med; 2009 Jan 22; 360(4):417; author reply 418. PubMed ID: 19172674
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.